Listed

Inhibikase Therapeutics, Inc.

IKTNasdaqCIK 1750149HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q2 FY2026
Operating income−$21.1m, Q2 FY2026
Net income−$19.6m, Q2 FY2026
Inhibikase Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m0.1Revenue, Q3 FY2023, three months to 2023-09-30$79.6k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2023-11-14, accession 0000950170-23-063713.Report this figure0.0Revenue, Q4 FY2023, three months to 2023-12-31$1. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-27, accession 0000950170-25-046096. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-14, accession 0000950170-25-071635.Report this figure0.0Revenue, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-14, accession 0001193125-25-180899.Report this figure0.0Revenue, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure0.0Revenue, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-27, accession 0000950170-25-046096. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure0.0Revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure0.0Revenue, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figurenot reported0.0Revenue, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure0.0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure
Research and development$m3.2Research and development, Q3 FY2023, three months to 2023-09-30$3.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2023-11-14, accession 0000950170-23-063713.Report this figure3.0Research and development, Q4 FY2023, three months to 2023-12-31$3.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-27, accession 0000950170-25-046096. Derived: 12-month figure less the 9-month figure.Report this figure2.8Research and development, Q1 FY2024, three months to 2024-03-31$2.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-14, accession 0000950170-25-071635.Report this figure3.1Research and development, Q2 FY2024, three months to 2024-06-30$3.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-14, accession 0001193125-25-180899.Report this figure4.2Research and development, Q3 FY2024, three months to 2024-09-30$4.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure7.2Research and development, Q4 FY2024, three months to 2024-12-31$7.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-26, accession 0001193125-26-126371. Derived: 12-month figure less the 9-month figure.Report this figure10.5Research and development, Q1 FY2025, three months to 2025-03-31$10.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure5.3Research and development, Q2 FY2025, three months to 2025-06-30$5.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure7.6Research and development, Q3 FY2025, three months to 2025-09-30$7.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure6.4Research and development, Q4 FY2025, three months to 2025-12-31$6.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-26, accession 0001193125-26-126371. Derived: 12-month figure less the 9-month figure.Report this figure10.8Research and development, Q1 FY2026, three months to 2026-03-31$10.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure13.4Research and development, Q2 FY2026, three months to 2026-06-30$13.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure
Selling, general and administrative$m1.6Selling, general and administrative, Q3 FY2023, three months to 2023-09-30$1.6m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2023-11-14, accession 0000950170-23-063713.Report this figure1.4Selling, general and administrative, Q4 FY2023, three months to 2023-12-31$1.4m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2025-03-27, accession 0000950170-25-046096. Derived: 12-month figure less the 9-month figure.Report this figure2.0Selling, general and administrative, Q1 FY2024, three months to 2024-03-31$2.0m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-05-14, accession 0000950170-25-071635.Report this figure2.0Selling, general and administrative, Q2 FY2024, three months to 2024-06-30$2.0m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-08-14, accession 0001193125-25-180899.Report this figure1.6Selling, general and administrative, Q3 FY2024, three months to 2024-09-30$1.6m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure5.7Selling, general and administrative, Q4 FY2024, three months to 2024-12-31$5.7m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-03-26, accession 0001193125-26-126371. Derived: 12-month figure less the 9-month figure.Report this figure5.2Selling, general and administrative, Q1 FY2025, three months to 2025-03-31$5.2m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure5.9Selling, general and administrative, Q2 FY2025, three months to 2025-06-30$5.9m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure5.6Selling, general and administrative, Q3 FY2025, three months to 2025-09-30$5.6m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure6.8Selling, general and administrative, Q4 FY2025, three months to 2025-12-31$6.8m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-03-26, accession 0001193125-26-126371. Derived: 12-month figure less the 9-month figure.Report this figure7.4Selling, general and administrative, Q1 FY2026, three months to 2026-03-31$7.4m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure7.7Selling, general and administrative, Q2 FY2026, three months to 2026-06-30$7.7m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure
Operating income$m(4.8)Operating income, Q3 FY2023, three months to 2023-09-30−$4.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2023-11-14, accession 0000950170-23-063713.Report this figure(4.4)Operating income, Q4 FY2023, three months to 2023-12-31−$4.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-27, accession 0000950170-25-046096. Derived: 12-month figure less the 9-month figure.Report this figure(4.8)Operating income, Q1 FY2024, three months to 2024-03-31−$4.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-14, accession 0000950170-25-071635.Report this figure(5.1)Operating income, Q2 FY2024, three months to 2024-06-30−$5.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-14, accession 0001193125-25-180899.Report this figure(5.8)Operating income, Q3 FY2024, three months to 2024-09-30−$5.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure(12.9)Operating income, Q4 FY2024, three months to 2024-12-31−$12.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-26, accession 0001193125-26-126371. Derived: 12-month figure less the 9-month figure.Report this figure(14.6)Operating income, Q1 FY2025, three months to 2025-03-31−$14.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure(10.8)Operating income, Q2 FY2025, three months to 2025-06-30−$10.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure(12.8)Operating income, Q3 FY2025, three months to 2025-09-30−$12.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure(13.8)Operating income, Q4 FY2025, three months to 2025-12-31−$13.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-26, accession 0001193125-26-126371. Derived: 12-month figure less the 9-month figure.Report this figure(17.8)Operating income, Q1 FY2026, three months to 2026-03-31−$17.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure(21.1)Operating income, Q2 FY2026, three months to 2026-06-30−$21.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure
Interest expense$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$m0.0Income tax, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-14, accession 0000950170-24-126766.Report this figurenot reported0.0Income tax, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-14, accession 0000950170-25-071635.Report this figure0.0Income tax, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-08-14, accession 0000950170-24-097022.Report this figure0.0Income tax, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure0.0Income tax, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-26, accession 0001193125-26-126371. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure0.0Income tax, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure0.0Income tax, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure0.0Income tax, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-26, accession 0001193125-26-126371. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure0.0Income tax, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure
Net income$m(4.6)Net income, Q3 FY2023, three months to 2023-09-30−$4.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-14, accession 0000950170-24-126766.Report this figure(4.2)Net income, Q4 FY2023, three months to 2023-12-31−$4.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-27, accession 0000950170-25-046096. Derived: 12-month figure less the 9-month figure.Report this figure(4.6)Net income, Q1 FY2024, three months to 2024-03-31−$4.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure(5.0)Net income, Q2 FY2024, three months to 2024-06-30−$5.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure(5.8)Net income, Q3 FY2024, three months to 2024-09-30−$5.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure(12.1)Net income, Q4 FY2024, three months to 2024-12-31−$12.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-26, accession 0001193125-26-126371. Derived: 12-month figure less the 9-month figure.Report this figure(13.7)Net income, Q1 FY2025, three months to 2025-03-31−$13.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure(9.9)Net income, Q2 FY2025, three months to 2025-06-30−$9.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure(11.9)Net income, Q3 FY2025, three months to 2025-09-30−$11.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure(12.7)Net income, Q4 FY2025, three months to 2025-12-31−$12.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-26, accession 0001193125-26-126371. Derived: 12-month figure less the 9-month figure.Report this figure(16.4)Net income, Q1 FY2026, three months to 2026-03-31−$16.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure(19.6)Net income, Q2 FY2026, three months to 2026-06-30−$19.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure
Diluted EPS$ per share(0.86)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.86 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2023-11-14, accession 0000950170-23-063713.Report this figurenot reported(0.73)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.73 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-14, accession 0000950170-25-071635.Report this figure(0.66)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.66 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-14, accession 0001193125-25-180899.Report this figure(0.65)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.65 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figurenot reported(0.15)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure(0.11)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure(0.13)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figurenot reported(0.10)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure(0.11)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure
Basic EPS$ per share(0.86)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.86 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2023-11-14, accession 0000950170-23-063713.Report this figurenot reported(0.73)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.73 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-14, accession 0000950170-25-071635.Report this figure(0.66)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.66 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-14, accession 0001193125-25-180899.Report this figure(0.65)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.65 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figurenot reported(0.15)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.15 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure(0.11)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure(0.13)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.13 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figurenot reported(0.10)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.10 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure(0.11)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure

Balance sheet

Cash and equivalents$31.2m, Q2 FY2026
Long-term debt$381.8k, FY2023
Shareholders' equity$153.3m, Q2 FY2026
Inhibikase Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m14.9Cash and equivalents, Q3 FY2023, at 2023-09-30$14.9m. XBRL concept us-gaap:Cash. 10-Q filed 2023-11-14, accession 0000950170-23-063713.Report this figure9.2Cash and equivalents, FY2023, at 2023-12-31$9.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-27, accession 0000950170-25-046096.Report this figure2.4Cash and equivalents, Q1 FY2024, at 2024-03-31$2.4m. XBRL concept us-gaap:Cash. 10-Q filed 2024-05-15, accession 0000950170-24-060579.Report this figure3.1Cash and equivalents, Q2 FY2024, at 2024-06-30$3.1m. XBRL concept us-gaap:Cash. 10-Q filed 2024-08-14, accession 0000950170-24-097022.Report this figure0.9Cash and equivalents, Q3 FY2024, at 2024-09-30$913.4k. XBRL concept us-gaap:Cash. 10-Q filed 2024-11-14, accession 0000950170-24-126766.Report this figure97.5Cash and equivalents, FY2024, at 2024-12-31$97.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-26, accession 0001193125-26-126371.Report this figure73.4Cash and equivalents, Q1 FY2025, at 2025-03-31$73.4m. XBRL concept us-gaap:Cash. 10-Q filed 2025-05-14, accession 0000950170-25-071635.Report this figure77.7Cash and equivalents, Q2 FY2025, at 2025-06-30$77.7m. XBRL concept us-gaap:Cash. 10-Q filed 2025-08-14, accession 0001193125-25-180899.Report this figure38.3Cash and equivalents, Q3 FY2025, at 2025-09-30$38.3m. XBRL concept us-gaap:Cash. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure179Cash and equivalents, FY2025, at 2025-12-31$178.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-26, accession 0001193125-26-126371.Report this figure49.6Cash and equivalents, Q1 FY2026, at 2026-03-31$49.6m. XBRL concept us-gaap:Cash. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure31.2Cash and equivalents, Q2 FY2026, at 2026-06-30$31.2m. XBRL concept us-gaap:Cash. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure
Current assets$m17.6Current assets, Q3 FY2023, at 2023-09-30$17.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-14, accession 0000950170-23-063713.Report this figure14.2Current assets, FY2023, at 2023-12-31$14.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-27, accession 0000950170-25-046096.Report this figure10.8Current assets, Q1 FY2024, at 2024-03-31$10.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-15, accession 0000950170-24-060579.Report this figure8.6Current assets, Q2 FY2024, at 2024-06-30$8.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-14, accession 0000950170-24-097022.Report this figure4.2Current assets, Q3 FY2024, at 2024-09-30$4.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-14, accession 0000950170-24-126766.Report this figure98.5Current assets, FY2024, at 2024-12-31$98.5m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-26, accession 0001193125-26-126371.Report this figure94.2Current assets, Q1 FY2025, at 2025-03-31$94.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-14, accession 0000950170-25-071635.Report this figure88.8Current assets, Q2 FY2025, at 2025-06-30$88.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-14, accession 0001193125-25-180899.Report this figure78.5Current assets, Q3 FY2025, at 2025-09-30$78.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure180Current assets, FY2025, at 2025-12-31$180.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure172Current assets, Q1 FY2026, at 2026-03-31$172.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure162Current assets, Q2 FY2026, at 2026-06-30$162.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure
Total assets$m17.9Total assets, Q3 FY2023, at 2023-09-30$17.9m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-14, accession 0000950170-23-063713.Report this figure14.5Total assets, FY2023, at 2023-12-31$14.5m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-27, accession 0000950170-25-046096.Report this figure11.1Total assets, Q1 FY2024, at 2024-03-31$11.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-15, accession 0000950170-24-060579.Report this figure8.8Total assets, Q2 FY2024, at 2024-06-30$8.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-14, accession 0000950170-24-097022.Report this figure4.4Total assets, Q3 FY2024, at 2024-09-30$4.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-14, accession 0000950170-24-126766.Report this figure98.6Total assets, FY2024, at 2024-12-31$98.6m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-26, accession 0001193125-26-126371.Report this figure94.3Total assets, Q1 FY2025, at 2025-03-31$94.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-14, accession 0000950170-25-071635.Report this figure88.9Total assets, Q2 FY2025, at 2025-06-30$88.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-14, accession 0001193125-25-180899.Report this figure79.6Total assets, Q3 FY2025, at 2025-09-30$79.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure181Total assets, FY2025, at 2025-12-31$181.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure173Total assets, Q1 FY2026, at 2026-03-31$173.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure164Total assets, Q2 FY2026, at 2026-06-30$163.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure
Current liabilities$m2.7Current liabilities, Q3 FY2023, at 2023-09-30$2.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-14, accession 0000950170-23-063713.Report this figure3.4Current liabilities, FY2023, at 2023-12-31$3.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-27, accession 0000950170-25-046096.Report this figure4.2Current liabilities, Q1 FY2024, at 2024-03-31$4.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-15, accession 0000950170-24-060579.Report this figure3.7Current liabilities, Q2 FY2024, at 2024-06-30$3.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-14, accession 0000950170-24-097022.Report this figure4.9Current liabilities, Q3 FY2024, at 2024-09-30$4.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-14, accession 0000950170-24-126766.Report this figure3.7Current liabilities, FY2024, at 2024-12-31$3.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-26, accession 0001193125-26-126371.Report this figure8.6Current liabilities, Q1 FY2025, at 2025-03-31$8.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-14, accession 0000950170-25-071635.Report this figure8.8Current liabilities, Q2 FY2025, at 2025-06-30$8.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-14, accession 0001193125-25-180899.Report this figure6.7Current liabilities, Q3 FY2025, at 2025-09-30$6.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure8.3Current liabilities, FY2025, at 2025-12-31$8.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure5.7Current liabilities, Q1 FY2026, at 2026-03-31$5.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure10.3Current liabilities, Q2 FY2026, at 2026-06-30$10.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure
Total liabilities$m2.9Total liabilities, Q3 FY2023, at 2023-09-30$2.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-14, accession 0000950170-23-063713.Report this figure3.5Total liabilities, FY2023, at 2023-12-31$3.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-27, accession 0000950170-25-046096.Report this figure4.3Total liabilities, Q1 FY2024, at 2024-03-31$4.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-15, accession 0000950170-24-060579.Report this figure3.7Total liabilities, Q2 FY2024, at 2024-06-30$3.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-14, accession 0000950170-24-097022.Report this figure4.9Total liabilities, Q3 FY2024, at 2024-09-30$4.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-14, accession 0000950170-24-126766.Report this figure3.7Total liabilities, FY2024, at 2024-12-31$3.7m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-26, accession 0001193125-26-126371.Report this figure8.6Total liabilities, Q1 FY2025, at 2025-03-31$8.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-14, accession 0000950170-25-071635.Report this figure8.8Total liabilities, Q2 FY2025, at 2025-06-30$8.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-14, accession 0001193125-25-180899.Report this figure6.7Total liabilities, Q3 FY2025, at 2025-09-30$6.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure8.3Total liabilities, FY2025, at 2025-12-31$8.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure5.7Total liabilities, Q1 FY2026, at 2026-03-31$5.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure10.3Total liabilities, Q2 FY2026, at 2026-06-30$10.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure
Long-term debt$mnot reported0.4Long-term debt, FY2023, at 2023-12-31$381.8k. XBRL concept us-gaap:LongTermDebt. 10-K filed 2024-03-27, accession 0000950170-24-037160.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m15.0Shareholders' equity, Q3 FY2023, at 2023-09-30$15.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-14, accession 0000950170-24-126766.Report this figure11.0Shareholders' equity, FY2023, at 2023-12-31$11.0m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-26, accession 0001193125-26-126371.Report this figure6.8Shareholders' equity, Q1 FY2024, at 2024-03-31$6.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure5.1Shareholders' equity, Q2 FY2024, at 2024-06-30$5.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure(0.5)Shareholders' equity, Q3 FY2024, at 2024-09-30−$530.6k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure94.9Shareholders' equity, FY2024, at 2024-12-31$94.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure85.7Shareholders' equity, Q1 FY2025, at 2025-03-31$85.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure80.1Shareholders' equity, Q2 FY2025, at 2025-06-30$80.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure72.9Shareholders' equity, Q3 FY2025, at 2025-09-30$72.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure173Shareholders' equity, FY2025, at 2025-12-31$172.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure168Shareholders' equity, Q1 FY2026, at 2026-03-31$167.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure153Shareholders' equity, Q2 FY2026, at 2026-06-30$153.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure

Cash flow

Operating cash flow−$12.4m, Q2 FY2026
Capital expenditure$0, Q2 FY2026
Inhibikase Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(4.1)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$4.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-14, accession 0000950170-24-126766. Derived: 9-month figure less the 6-month figure.Report this figure(3.4)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$3.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-27, accession 0000950170-25-046096. Derived: 12-month figure less the 9-month figure.Report this figure(3.9)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$3.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-14, accession 0000950170-25-071635.Report this figure(5.1)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$5.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-14, accession 0001193125-25-180899. Derived: 6-month figure less the 3-month figure.Report this figure(4.9)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$4.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001193125-25-283169. Derived: 9-month figure less the 6-month figure.Report this figure(5.3)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$5.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001193125-26-126371. Derived: 12-month figure less the 9-month figure.Report this figure(4.1)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$4.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure(5.6)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$5.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001193125-26-344707. Derived: 6-month figure less the 3-month figure.Report this figure(10.6)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$10.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001193125-25-283169. Derived: 9-month figure less the 6-month figure.Report this figure(7.5)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$7.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001193125-26-126371. Derived: 12-month figure less the 9-month figure.Report this figure(12.1)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$12.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure(12.4)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$12.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001193125-26-344707. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-14, accession 0000950170-24-126766. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-27, accession 0000950170-25-046096. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-14, accession 0000950170-25-071635.Report this figure0.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-14, accession 0001193125-25-180899. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-14, accession 0001193125-25-283169. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-26, accession 0001193125-26-126371. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$13.4k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001193125-26-344707. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-14, accession 0001193125-25-283169. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-26, accession 0001193125-26-126371. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001193125-26-344707. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)174.57m, Q2 FY2026
Inhibikase Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares4.2Diluted shares (weighted), Q3 FY2022, three months to 2022-09-304,224,294 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-14, accession 0000950170-23-063713.Report this figure4.6Diluted shares (weighted), Q1 FY2023, three months to 2023-03-314,585,013 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-15, accession 0000950170-24-060579.Report this figure5.2Diluted shares (weighted), Q2 FY2023, three months to 2023-06-305,226,101 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-08-14, accession 0000950170-23-042389.Report this figure5.3Diluted shares (weighted), Q3 FY2023, three months to 2023-09-305,342,337 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-14, accession 0000950170-23-063713.Report this figure6.3Diluted shares (weighted), Q1 FY2024, three months to 2024-03-316,340,697 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-14, accession 0000950170-25-071635.Report this figure7.5Diluted shares (weighted), Q2 FY2024, three months to 2024-06-307,535,667 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-14, accession 0001193125-25-180899.Report this figure8.9Diluted shares (weighted), Q3 FY2024, three months to 2024-09-308,882,570 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure89.5Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3189,537,171 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure90.0Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3090,009,625 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure90.1Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3090,050,973 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001193125-25-283169.Report this figure172Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31172,306,932 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-12, accession 0001193125-26-219641.Report this figure175Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30174,571,543 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure

Shares outstanding: 139.54mShares outstanding, period not labelled, at 2026-08-04139,535,900 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344707.Report this figure at Aug 4, 2026, from the cover of the 10-Q filed Aug 11, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. Listed shows no prices and gives no investment advice.